Exhibit
10.75


 


 





 


EXPLANATORY
NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT


THAT
HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND


(II)
WOULD BE COMPETITIVELY HARMFUL IN PUBLICLY DISCLOSED. 


 


 


 


Victoria
Scott, Director of Quality & Regulatory Affairs


 


2117
SW Highway 484


Ocala,
FL 34473


Corporate
Phone: (352) 448-7797


Corporate
Fax: (352)480-4620


 


Email:
Victoria.Scott@AIMimmuno.com


 


Submitted
By:


Pharmaceutics
International, Inc. (Pii)


Kevin
Kelly, Head of Sales


 


10819
Gilroy Road


Hunt
Valley, MD 21031


Corporate
Phone: (410) 584-0001


Mobile:
(610) 349-3745


 


Corporate
Fax: (410) 527-0525


Email:
kkelly@pharm-int.com


 


Project
Number 27AIM01


 


 




    	 



    	 



    

 


 


 





EXPLANATORY
NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT


THAT
HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND


(II)
WOULD BE COMPETITIVELY HARMFUL IN PUBLICLY DISCLOSED.


 


Executive
Summary 





 



 


Introduction:


 


Pharmaceutics
International, Inc. (Pii) is a solutions-oriented, science-driven Contract Development and Manufacturing Organization (CDMO),
with over 25 years of proven success in providing dosage form development and cGMP manufacturing services to the global biopharmaceutical
industry. Through continuous Investment and Innovation, Pii strives to be the preferred partner of choice for both injectable
and oral delivery drug products. Providing outstanding service and value, combined with our experience and relevant expertise,
makes Pii uniquely qualified to support product success for our partners.


 


Pii
Delivers Strong Value to its Partners:


 


A
Sustainable Business Partner:


 


	 	●	Over
    25 years of product development, regulatory approval and commercial production success
	 	●	Foundation
    in Pharmaceutics Know-How, applied to all programs and products 
	 	●	Broad
    partner base ranging from virtual and emerging Pharma to multi-national organizations
	 	●	Continued
    capital investments ($125M since 2016) with planned facility expansions


 


Compelling
Facilities:


 


	 	●	Over
    360,000 square feet of state-of-the-art product development and cGMP manufacturing space
	 	●	Containment
    suites for handling high potency compounds and hormones
	 	●	Formulation
    development center-of-excellence and fully-equipped analytical laboratories – all service offerings located in Hunt
    Valley, MD
	 	●	Registered
    with the DEA for Schedule I-V Controlled Substances


 


Compliant
Quality Systems & Processes:


 


	 	●	Ongoing
    investments & improvements toward the highest quality & compliance standards
	 	●	FDA,
    MHRA, EMA inspected facilities with 11 new product approvals since 2017
	 	●	Audit
    history with Regulatory Agencies and Partners 


 


Science
& Innovation Driven:


 


	 	●	Highly
    skilled team of seasoned industry leaders
	 	●	Unparalleled
    depth of scientific training, project management and enterprise-wide experience brought to every program and partner
	 	●	Solutions
    provider with an unwavering commitment to exceeding every partners’ expectations 


 


Flexible
& Reliable: 


 


	 	●	Product
    development tailored to the characteristics of the API and partners’ objectives
	 	●	Project
    timelines driven by agreed upon milestones and development strategies
	 	●	Demonstrated
    speed to Clinic as well as sustainable Commercial supply


 




    	27AIM01.01
	December 22, 2020	Page 2 of 27
	 	CONFIDENTIAL	 



    	 



    

 


Primary
Contacts 


 






 


	Name	 	Title	 	Phone
    Number	 	Email
    Address
	Kevin Kelly	 	Head of Sales	 	[***]	 	[***]
	 	 	 	 	 	 	 
	Devan Patel	 	Sr. Director,
    Project Management	 	[***]	 	[***]
	 	 	 	 	 	 	 
	Trish Petty	 	Accounts Receivable
    Billing/Collections Specialist	 	[***]	 	[***]



 




    	27AIM01.01
	December 22, 2020	Page 3 of 27
	 	CONFIDENTIAL	 



    	 



    

 


This
proposal is comprised of three sections, which together are this “Agreement”:


 


	I.	Project
    Definition and Scope
	II.	Timing
    and Project Initiation
	III.	Costs
	IV.	Legal
    and Signatures


 


Quotation
is valid for thirty (30) days


 


I.
Project Definition and Scope


 


AIM
ImmunoTech Inc., (“Client” or “Customer”) requests Pharmaceutics International, Inc., (“Pii”)
to perform technical transfer supporting cGMP manufacturing services of Ampligen (Rintatolimod) Sterile Solution 2.5mg/mL for
AIM ImmunoTech, Inc.


 


Indication:
Severely debilitated patients with chronic fatigue syndrome (cfs)


 


Intended
Country of Distribution: United States


 


“Product”
in this Agreement refers to “Ampligen (Rintatolimod) Sterile Solution 2.5mg/mL”


 


Active
Pharmaceutical Ingredient (“API”) refers to “Rintatolimod”


 


API
Handling: Store at “-20°C”


 


Finished
Product Handling: Store at “Store at 2-8°C”


 


	1.	Environmental
    Health and Safety (EH&S) Assessment


 


	 	1.1	Pii
    will conduct an environmental health and safety (EH&S) assessment. If a certifiable toxicologist report that includes
    both Occupational Exposure Limit (OEL) and Acceptable Daily Exposure (ADE) values cannot be provided by AIM ImmunoTech Inc.,
    then an outside toxicologist will assess the API and calculate both an OEL and ADE value. The OEL value will be used to assess
    the level of containment needed to safely manufacture the Product, per Pii’s SOP. The ADE value, will be used to calculate
    an acceptable residual limit per Pii’s SOP for cleaning and to evaluate potential for cross-contamination.


 




    	27AIM01.01
	December 22, 2020	Page 4 of 27
	 	CONFIDENTIAL	 



    	 



    

 


	2.	Materials
                                         

         

        Intended
        Country of Distribution: United States



 


	 	2.1	AIM
    ImmunoTech Inc. will supply:


 


	 	●	Background
    Summary
	 	●	API
    with Certificate of Analysis (“C of A”), Safety Data Sheet (“SDS”), Bovine Spongiform Encephalopathy/Transmissible
    Spongiform Encephalopathy Statement (“BSE/TSE”), Melamine statement and all other supporting documentation available
	 	●	The
    cost of API
	 	 	Poly
    I is $[***] per gram
	 	 	Poly
    C12U is $[***] per gram
	 	●	Analytical
    Methods 
	 	●	Reference
    standard and impurities 
	 	●	Drug
    product technical data package if any 
	 	●	API
    DMF and/or technical data package from the manufacturer or the Client, if any 
	 	●	Safety
    Information: Investigator's Brochure or Summaries of Pre-clinical safety/activity data, where available, including: 





	 	○	Safety
    Pharmacology Studies
	 	○	Mutagenicity
    Studies (e.g. AMES test
	 	○	Non-GLP
    and/or GLP acute and sub-chronic/chronic toxicity trials in any
	 	○	Pharmacology
    Summary
	 	○	Teratogenicity
    Studies 





	 	● 	The
    above information will be used to determine allowable residual carryover limits used in cleaning validation and to determine
    the appropriate level of containment and personal protection equipment (PPE) required.


 


	 	2.2	Pii
    will order and invoice to AIM ImmunoTech Inc.: (Reference under Cost Sections)


 


		●	API
    (If requested by AIM ImmunoTech Inc.)
		●	Excipients
		●	Packaging
    Components
		●	Analytical
    Columns
		●	Tooling,
    Change Parts (if required)
		●	Capital
    Equipment (if needed with AIM ImmunoTech Inc.'s authorization)
		●	Personal
    Protective Equipment (if required)
		●	Disposables


 




    	27AIM01.01
	December 22, 2020	Page 5 of 27
	 	CONFIDENTIAL	 



    	 



    




 


	 	2.3	API
    - Pii will receive with manufacturer’s Certificate of Analysis (C of A) and will release from vendor CoA for use
    in R&D Lab Batch(es). Pii will perform Full Release per approved specification for use in cGMP batch(es).
	 	2.4	Excipients
    - Pii will receive with manufacturer’s Certificate of Analysis (C of A) and will release from vendor CoA for use
    in R&D Lab Batch(es). Pii will perform Full Release per approved specification for use in cGMP batch(es).
	 	2.5	Packaging
                                         - Pii will receive with manufacturer’s Certificate of Analysis (C of A) and
                                         will release from vendor CoA for use in R&D Lab Batch(es). Pii will perform Full
                                         Release per approved specification for use in cGMP batch(es).

         

        Any
        item or service (e.g. API, excipient, analytical testing) specified by AIM ImmunoTech Inc. that differs from Pii's provider,
        requires a GMP evaluation by AIM ImmunoTech Inc., that the supplier of the item or service has been found to be in substantial
        compliance with the applicable national regulations (e.g. US, EU, JP). If applicable, the Pii Master Quality Agreement
        will elaborate further on this and other "Quality Agreement" requirements.



 


	3.	Analytical
    Support


 


	 	3.1	Evaluation
    of each test in regards to validation requirements: Pii will review analytical methods proposed and conduct an evaluation
    to assess the levels and types of validation that are phase appropriate for the new drug product for each test required. This
    assures compliance with regulatory guidance depending on the phase of research. AIM ImmunoTech Inc. needs to allow for four
    to five weeks at the initiation of the project for analytical methods evaluation.
	 	3.2	Cleaning
    Method: Pii will develop an analytical method to evaluate the effectiveness of the cleaning procedure and perform validation
    of the analytical method. This includes recovery studies from materials similar to the surfaces of cGMP equipment that is
    to be used for this program.
	 	3.3	API
    Methods: Pii will review the manufacturer’s C of A and methods. Pii will perform ID and Micro only on the incoming
    Drug substance/Polymers based on package received from AIM ImmunoTech Inc.: 


 


		●	Microbial
    enumeration (USP 61)
		●	Bacterial
    Endotoxin
		●	ID
    by UV


 




    	27AIM01.01
	December 22, 2020	Page 6 of 27
	 	CONFIDENTIAL	 



    	 



    

  


	 	3.4	Drug
    Product Methods: Pii will perform Method Transfer (where applicable), and will perform USP Method Verification(where applicable)
    of the following methods: 


 


	 	●	Bacterial
    Endotoxin
	 	●	Sterility


 


	 	 	USP
    testing is expected to be conducted for these tests. Any product specific testing or compendial testing outside of USP will
    require additional development and testing procedures. 





	 	3.5	Analytical
    Method: perform ID and Micro Only Protocols for the drug product will be prepared by Pii and approved by AIM ImmunoTech
    Inc. if required.
	 	3.6	Method
    Transfer





	 	●	Method
    Transfer Pre-requisite:





	 	○	Method
    has been established
	 	○	Method
    has been validated
	 	○	Validation
    report/package is available for review
	 	○	Method
    transfer process will be supported by the laboratory where the method had been established. Method precision samples will
    be tested concurrently by Pii and this laboratory.


 


	4.	Technical
                                         Transfer/Process Development

        Number
        of Primary Prototype(s): 1 experiment



 


	 	4.1	Pii
    will review the technical data package supplied by AIM ImmunoTech Inc. and will develop a plan outlining the process development
	 	4.2	Pii
    will develop formulation(s) based on the agreed-to Formulation Development Plan.
	 	4.3	Pii
    will perform: 





	 	●	Cleaning
    activities/requirements to support a Quality Risk Management Plan (QRMP) to ensure cross contamination controls are in place
    for cGMP production.


 


	 	4.4	Based
    upon the data generated, Pii and AIM ImmunoTech Inc. will make a decision on how to proceed on the formulation and process.


 




    	27AIM01.01
	December 22, 2020	Page 7 of 27
	 	CONFIDENTIAL	 



    	 



    


 


	5.	(OPTIONAL)
                                         Manufacture of Technical Transfer Batch

        Strengths:
        2.5mg/mL

        Theoretical
        Batch Size: up to 750L

        No.
        Batches: 1



 


	 	5.1	Pii
    will manufacture 1 technical transfer batch.
	 	5.2	Material
    Testing Requirements: See Section 2.
	 	5.3	All
    manufacturing activities will be recorded in a batch record.
	 	5.4	Pii
    will use equipment train based on the proposed process from Section 6.
	 	5.5	Pii
    will perform the following in-process tests:


 


	 	●	Density
	 	●	Bioburden
	 	●	Osmolality
	 	●	UV


 


	 	5.6	Pii
    will perform the following finished product tests:


 


	 	●	Bacterial
    Endotoxin
	 	●	Sterility


 


	 	5.7	Based
    upon the data generated, Pii and AIM ImmunoTech Inc. will mutually agree on how to proceed.


 


	6.	Manufacture
                                         of Submission Batches

        Strength:
        2.5mg/mL

        Theoretical
        Batch Size: up to 750L

        No.
        Batches: 3



 


	 	6.1	All
    materials used for the manufacture of the batches will be fully released by Pii unless otherwise specified by AIM ImmunoTech
    Inc.. See Materials: Section 2.
	 	6.2	Pii
    will prepare master production records (MPR) based on the experience of manufacturing the batch(es). The batch records will
    be approved by AIM ImmunoTech Inc. at least one (1) week prior to the manufacture.
	 	6.3	The
    batches will be manufactured under cGMP conditions as directed in the production records.
	 	6.4	Pii
    will perform the following in-process tests on the active batches: 





	 	●	Density
	 	●	Bioburden


 


	 	6.5	Pii
    will perform the following finished product tests or as per the specifications: 


 


	 	●	Bacterial
    Endotoxin
	 	●	Sterility


 




    	27AIM01.01
	December 22, 2020	Page 8 of 27
	 	CONFIDENTIAL	 



    	 



    

 


EXPLANATORY
NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT


THAT
HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND


(II)
WOULD BE COMPETITIVELY HARMFUL IN PUBLICLY DISCLOSED.



 


	7.	Stability
                                         Program for Submission Batches

        No.
        Stability Protocols: 6 protocols [3 batches x 2 configurations] 

        [Upright
        and Inverted]



 


	 	7.1	Stability
    of the Active Packaged Product:


 


	 	●	Pii
    will prepare a protocol for each batch & configuration, which will be approved by the Client. The stability program is
    to be initiated as soon as the batch(es) are manufactured, primary/secondary packaged and each protocol is signed. If additional
    points are needed, they will be billed at the point charge rate.
	 	 	 
	 	●	Sufficient
    samples will be placed on stability to meet the stability protocol requirements. The stability protocols will include the
    following conditions and time point(s):


 





	Conditions	Initial
    *	6
    month	12
    month	18
    month	24
    month	30
    month	36
    month	42
    month	48
    month	54
    month	60
    month
	[***]	 

        m
	 m	 m	m	 m	m	 m	m	m	m	m
	[***]	 	 m	 m	 	 	 	 	 	 	 	 


  


	 	 	x
    – Test (Inverted/Upright) m – Microbial





	 	 	*
    Release data will be used at initial time if stability is initiated within one (1) month from manufacture


 


	 	 	The
    following tests will be performed on the batch(es), if not specified in the approved protocol otherwise:


 


	 	●	Bacterial
    Endotoxin
	 	●	Sterility


 




    	27AIM01.01
	December 22, 2020	Page 9 of 27
	 	CONFIDENTIAL	 



    	 



    

 


	8.	(OPTIONAL)
    Process Validation Studies


 


	 	8.1	Pii
    will prepare validation protocols, based on the engineering batch, which will be reviewed and approved by Eagle Pharmaceuticals,
    Inc. prior to beginning the validation batches.





	 	■	Process
    Validation Protocol will be generated to assess the following:





	 	○	Manufacturing
    process validation
	 	○	Mixing
    Study





	 	■	Evaluating
    the in-process tests/CQA’s





	 	○	In-Process
    testing as per the Batch Record
	 	○	In-Process
    checks for sterility, assay, and impurities for beginning, middle, and end samples for a total of 3 samples.
	 	○	Filtration





	 	■	Filter
    Flush Studies (if not previously performed)





	 	●	Evaluate
    particulate matter, moisture content, assay, impurities for up to 3 samples of appropriate flush volume





	 	○	Sample
    evaluation for filtration step (assumes filter assembly change out) for beginning, middle, and end samples for a total of
    3 samples.
	 	○	Finished
    Product Testing


 


	9.	Project
    Management


 


	 	9.1	The
    project kickoff meeting is the first opportunity for AIM ImmunoTech Inc. and Pii to perform a detailed review of all of the
    items required in making the project successful. In our experience, many clients make scope adjustments at this point of the
    project. It is for this reason that all quotations and project timelines communicated by Pii to AIM ImmunoTech Inc. are subject
    to revision until the project scope is finalized during the project kickoff meeting.
	 	9.2	Pii
    runs each project through project teams. This method has a proven record of success. The personnel selected as team representatives
    will have a direct impact on the level of success of the project. AIM ImmunoTech Inc. and Pii are responsible for selecting
    the appropriate personnel to represent each company. Expectations of members will include team and meeting participation,
    knowledge of the project and plan, maintaining open communication with other team members, following up on requests of the
    team, and building a positive working relationship between companies. Additionally, in order to maintain effective communication
    once a project has been initiated, Pii requests that all AIM ImmunoTech Inc. project inquiries be communicated through the
    Pii project leader. 


 




    	27AIM01.01
	December 22, 2020	Page 10 of 27
	 	CONFIDENTIAL	 



    	 



    

 


	 	●	Initiation
    of signed Agreement





	 	○	Business
    Development Kick-Off
	 	○	Review
    Agreement
	 	○	Background
    information from Business Manager
	 	○	Additional
    requirements





	 	●	Internal
    Pii Kick-Off meeting





	 	○	Functional
    Team Members identified
	 	○	Review
    Agreement
	 	○	Assemble
    needs/concerns





	 	●	Kick-Off
    Meeting with AIM ImmunoTech Inc.





	 	○	Review
    Agreement
	 	○	Agenda
    driven
	 	○	High-level
    timeline presented
	 	○	Agree
    to communication strategy
	 	○	Agree
    to timeline/schedule





	 	●	Ongoing
    Project Management





	 	○	Agree
    to regular project meetings





	 	■	Agendas
	 	■	Timelines
	 	■	Meeting
    notes





	 	○	On-going
    monitoring/reporting
	 	○	Billing/review
    & sign off on invoices
	 	○	Initiate
    stability protocols


 


	 	9.3	Provided
    that there are ongoing billable activities taking place (excluding stability), Pii will provide Project Management support
    to monitor the progress of the project against established timelines and will provide AIM ImmunoTech Inc. with updates. The
    Project Manager will coordinate with Pii’s project team and AIM ImmunoTech Inc. and commit up to two 45 minute teleconference
    meetings per month. The fee for Project Management is included in Section II: Cost. 


 




    	27AIM01.01
	December 22, 2020	Page 11 of 27
	 	CONFIDENTIAL	 



    	 



    

 


	10.	General
    Support


 


	 	10.1	cGMP
    batch records will be prepared by Pii and approved by AIM ImmunoTech Inc. QA. Changes to the batch record(s) one (1) week
    prior to manufacturing could lead to additional charges.
	 	10.2	Pii
    Quality Assurance department will audit and ensure cGMP compliance for the manufacturing of the batches.
	 	10.3	Waste
    from the manufacturing process will be incinerated. Any unused excipients will be destroyed after expiry date, as it arises.
	 	10.4	Pii
    will prepare necessary supporting CMC documentation for NDA submission using standard Pii report protocols. 
	 	10.5	Support
    for FDA deficiency letter responses and/or information requests will be charged at $[***]/hour. This may involve personnel
    from QA, technical operations, project management and/or executive oversight for these functions. Deficiency letter items
    may include revisions of test methods, drug substance specifications and drug product specifications, batch records, and technical
    writing support.
	 	10.6	Dedicated
    excipients and packaging components will be destroyed or shipped back to AIM ImmunoTech with prior authorization, three (3)
    months after completion of the manufacturing campaign(i.e., after completion of all 3 registration batches) . AIM ImmunoTech
    Inc. will be charged an incineration fee of $[***] per pallet for the destruction of materials. If however, AIM ImmunoTech
    Inc. elects to collect materials from Pii a $500 charge will apply.
	 	10.7	If
    AIM ImmunoTech Inc. elects for Pii to store finished product longer than three (3) months then there will be a storage charge
    of $[***]per month per pallet.


 


	II.	Timing
    and Project Initiation:


 


The
project will commence upon receipt of the signed Agreement, the drug substance, and the initiation payment, thereafter payments
are due thirty (30) days from the date of invoice. Unpaid balances shall bear interest at a rate of 18% per annum unless determined
not to be properly payable.


 


A
timeline will be provided once the Agreement is signed and the project kick-off meeting has been completed between Pii and the
AIM ImmunoTech Inc..


 




    	27AIM01.01
	December 22, 2020	Page 12 of 27
	 	CONFIDENTIAL	 



    	 



    

 


	III.	Cost:


 


The
cost table below lists the cost of each step of the program. If Pii and the AIM ImmunoTech Inc. mutually agree that any scope
changes or additional work is required, these additional activities will be covered under separate change order.


 


	Cost
    Table Estimates
	Pii
    Activity	Estimates	Subtotal
	1.	EH&S
    Assessment	 	 
	●   Environmental
    Health and Safety (EH&S) Assessment and QRMP	$[***]	$[***]
	2.	Analytical
    Support	 	 
	●   Cleaning
    – Develop and Validate	$[***]	$[***]
	●   Risk
                                         Assessment of Analytical Methods

        i)
        Review Validation Report 

        ●   API
        Methods – Perform ID and Micro Testing only on the API’s per section 3.3

        ●   Drug
        Product Methods – Method Transfer and USP qualification per section 3.4
	$[***]
	●   Documentation

        -
        Prepare Analytical Method Protocols

        -
        Reports (as required)

        -
        Methods/Specifications/SOP

	3.	Materials
    (Estimate – Actuals will be billed)	 	 
	API:

        ●   Full
        release testing will be charged at $12,000 / lot 

        ●   ID
        release at $3,500 / lot

        ●   Assumes
        the two polymers (APIs) will require ID and Micro only. Assumes only 3 lot of each drug substance. Assuming 3 lots of
        each drug substance x 2 APIs(polymers) x $3,500/lot =$21,000
	$[***]

         
	*Section
    3 is an estimate of material testing costs only. Actuals will be invoiced based upon usage or program specific materials being
    tested.
	Excipients:

        ●   USP/NF
        and EP/JP full release testing will be charged at $8,500 / lot 

        ●   PII
        will use stock excipients where applicable and may opt to charge on a per kg basis

        ●   Assumes
        use of 4 excipients with 1 lot only being full tested: Sodium Phosphate Dibasic-7-Hydrate, Sodium Phosphate Monobasic,
        Sodium Chloride, Magnesium Chloride Hexahydrate 

        ●   ID
        release at $1,500 / lot

         

         
	$[***]


 




    	27AIM01.01
	December 22, 2020	Page 13 of 27
	 	CONFIDENTIAL	 



    	 



    

 





	Cost
    Table Estimates
	Pii
    Activity	Estimates	Subtotal
	Packaging
                                         Components: 

        ●   USP/NF
        full release testing will be charged at $[***]/ lot 

        ●   PII
        will use stock components where applicable and may opt to charge on a per unit basis

        ●   Assumes
        one lot of vials, stoppers, and flip-off seals being fully released

        ●   ID
        release at $[***]/ lot
	$[***]	 
	Note:

        ●   Any
        outsourced testing not conducted at Pii for API, Excipients, or Packaging Components will be invoiced as a pass through
        + handling costs as per the terms of the agreement. 
	 
	4.	Tech
    Transfer/Process Development	 	 
	●   R/D
                                         Laboratory Manufacturing up to 5 L (1 experiment, notebook documentation)

        ●   Studies
        may include: 

        ○   Cleanability
        Assessment (support QRMP)

        ●   Analytical
        Support (testing as per section 4.4, if required)
	$[***]	$[***]
	5.	OPTIONAL:
    Manufacture of Feasibility Batch	 	 
	●   Manufacturing
                                         of 1 batch ($[***]per batch)

        ●   In-process
        testing

        ●   Finished
        Product Testing
	$[***]	 
	●   Documentation

        ●   Manufacturing
        Protocol 

        ●   Draft
        Batch Records)

	6.	Manufacture
    of Registration Batches	 	 
	●   Manufacturing
                                         of 3 cGMP Registration batches ($183,750 per batch)

        ●   In-process
        testing

        ●   Finished
        Product Testing
	$[***]	$[***]
	●   Documentation
                                         (#1)

        ●   Master
        Batch Records (MBR)

        ●   Certificate
        of Analysis and Certificate of Compliance

	●   (OPTIONAL)
                                         Process Validation Studies ($30,000 for PV studies)

        ●   Perform
        Process Validation Studies as outlined in section 8

        ●   Includes
        Process Validation Master Plan

        ●   Includes
        Process Validation Protocol and Report
	$[***]


 




    	27AIM01.01
	December 22, 2020	Page 14 of 27
	 	CONFIDENTIAL	 



    	 



    

 


	7.	Stability
    Program for Registration Batches	 	 
	Stability
    Programs (3 batches placed on stability at same time) 	 	 
	●   Stability
                                         60M Program 2-8C

        ●   Upright

        ○   Microbial
        Testing (10 pull points for upright x 3 batches x $[***])

        ●   Inverted:
        

        ○   Microbial
        Testing (10 pull points for inverted x 3 batches x $[***])

        ●   Stability
        12M Program 25C

        ●   Inverted:
        

        ○   Microbial
        Testing ( 2 pull points for inverted x 3 batches x $[***]))
	$[***]	$[***]
	8.	Project
    Management	 	 
	●   Project
                                         Timelines

        ●   The
        Project Manager will coordinate with Pii’s project team and the Client and commit up to two 45-minute teleconference
        meetings per month, and up to one quarterly face-to-face meeting.
	$[***]	$[***]
	9.	General
    Support 	 	 
	●   Administrative
                                         support (i.e., Change Controls)

        ●   Supply
        Chain Management (i.e., phase appropriate vendor qualification, procurement, sample handling)
	$[***]	$[***]
	 	 	 
	Sub-Total:	$[***]
	Estimated
                                         Costs for Pass Through:

        (for
        budgeting purposes only; Estimated at 15% of sub-total. Actuals will be billed as noted herein and excludes CAPEX that
        may be required)
	$[***]
	Materials
    Estimate (section 3):	$[***]
	 	 	 
	Estimated
    Project Total:	$[***]


 


In
addition to the above costs:


 


	 	●	AIM
    ImmunoTech Inc. shall pay to Pii upon receipt of Pii’s invoice by AIM ImmunoTech Inc. for all non-capital materials
    (excipients, packaging components, HPLC columns, analytical standards, microbial testing and tooling) used in the study at
    cost plus 10%. Pii shall obtain AIM ImmunoTech Inc.’s prior written approval for any expenditure greater than $[***].
    For high priced items more than $5,000, Pii will charge cost plus 5% to AIM ImmunoTech Inc.. Pii shall invoice AIM ImmunoTech
    Inc. for all reasonable and normal out-of-pocket travel-related expenses, including airfare, room & board, car rental
    and the like, of Pii during any technology transfer phase or project update meetings requested in advance by AIM ImmunoTech
    Inc.. 
	 	 	 
	 	●	Any
    OOS investigation and testing that is not considered to be Pii laboratory error after mutual review by both parties will be
    billed at a rate of $[***]/hour. Anything over 40 hours must be pre-approved by AIM.


 




    	27AIM01.01
	December 22, 2020	Page 15 of 27
	 	CONFIDENTIAL	 



    	 



    

 


	 	●	Any
    excipients, materials or components ordered as specialized items (not standard stock items) for use in the project will be
    invoiced in full to AIM ImmunoTech Inc.. A handling fee will apply as noted above. Payment is due within 30 days of receipt
    of invoice by AIM ImmunoTech Inc.. 
	 	 	 
	 	●	Any
    remaining stock of specialized items ordered on behalf of AIM ImmunoTech Inc. or shipped to Pii by AIM ImmunoTech Inc. will
    be shipped to AIM ImmunoTech Inc. upon notification by Pii. AIM ImmunoTech Inc. will be solely responsible for cost of shipment
    and a shipment preparation fee of $[***] will be applied.
	 	 	 
	 	●	Shipments
    outside of Agreement work scope will be invoiced as per the following:
	 	 	 
	 	a)	Shipment
    requests with three (3) day notice or more will be charged at $[***] plus shipping costs and a 10% service charge on shipping.
	 	 	 
	 	b)	Shipment
    requests with two (2) day notice will be charged at $[***] plus shipping costs and a 10% service charge on shipping.
	 	 	 
	 	c)	Shipment
    requests with twenty-four (24) hour notice will be charged at $[***] plus shipping costs and a 10% service charge on shipping.


 


Non-Stability
Payment Schedule


 


	Milestones	Activity	Amount
    Due
	 	Contract
                                         Initiation (non-refundable) for Ampligen (Rintatolimod) Sterile Solution 2.5mg/mL

        ●   Section
        1 @ $[***]

        ●   Section
        2 @ $[***]

        ●   Section
        4 @ $[***]

        ●   Section
        6 @ $[***]

        ●   Section
        8 @ $[***]

        ●   Section
        9 @ $[***]

         

        Please
        remit Contract Initiation payment along with signed Agreement to Pii.

         
	$[***]
	 	Initiation
                                         of Manufacture of Registration Batch #1 for Ampligen (Rintatolimod) Sterile Solution
                                         2.5mg/mL

         

        ●   Batch
        Record Issued to Manufacturing/Production at Pii

         
	 

        $[***]

	 	Completion
                                         of Manufacturing of Registration Batch #1 for Ampligen (Rintatolimod) Sterile Solution
                                         2.5mg/mL

         

        ●   Provision
        of Pii QA Reviewed Batch Record

         
	$[***]


 




    	27AIM01.01
	December 22, 2020	Page 16 of 27
	 	CONFIDENTIAL	 



    	 



    

 


 


	 	Disposition
                                         of Registration Batch #1 for Ampligen (Rintatolimod) Sterile Solution 2.5mg/mL

         

        ●   Pii
        QA Disposition Document for Batch

         

         
	$[***]
	 	Initiation
                                         of Manufacture of Registration Batch #2 for Ampligen (Rintatolimod) Sterile Solution
                                         2.5mg/mL

         

        ●   Batch
        Record Issued to Manufacturing/Production at Pii

         
	 

        $[***]

	 	Completion
                                         of Manufacturing of Registration Batch #2 for Ampligen (Rintatolimod) Sterile Solution
                                         2.5mg/mL

         

        ●   Provision
        of Pii QA Reviewed Batch Record

         
	 

        $[***]

	 	Disposition
                                         of Registration Batch #2 for Ampligen (Rintatolimod) Sterile Solution 2.5mg/mL

         

        ●   Pii
        QA Disposition Document for Batch

         
	 

        $[***]

	 	Initiation
                                         of Manufacture of Registration Batch #3 for Ampligen (Rintatolimod) Sterile Solution
                                         2.5mg/mL

         

        ●   Batch
        Record Issued to Manufacturing/Production at Pii

         
	 

        $[***]

	 	Completion
                                         of Manufacturing of Registration Batch #3 for Ampligen (Rintatolimod) Sterile Solution
                                         2.5mg/mL

         

        ●   Provision
        of Pii QA Reviewed Batch Record

         
	 

        $[***]

	 	Disposition
                                         of Registration Batch #3 for Ampligen (Rintatolimod) Sterile Solution 2.5mg/mL

         

        ●   Pii
        QA Disposition Document for Batch

         
	 

        $[***]

	OPTIONAL	Initiation
                                         of Manufacturing of Feasibility Batch of Ampligen (Rintatolimod) Sterile Solution 2.5mg/mL
                                         ($[***])

         

        ●   Draft
        Batch Record Sent to AIM ImmunoTech for Review

         
	 
	OPTIONAL	Completion
                                         of Manufacturing of Feasibility Batch of Ampligen (Rintatolimod) Sterile Solution 2.5mg/mL
                                         ($[***])

         

        ●   Draft
        of the Executed Batch Record Sent to AIM ImmunoTech for Review

         
	 
	OPTIONAL	Initiation
                                         of Process Validation Protocol for Ampligen (Rintatolimod) Sterile Solution 2.5mg/mL
                                         ($[***])

         

        ●   Draft
        of Process Validation Protocol sent to AIM ImmunoTech
	 
	OPTIONAL	Completion
                                         of Process Validation Protocol for Ampligen (Rintatolimod) Sterile Solution 2.5mg/mL
                                         ($[***])

         

        ●   Draft
        of the Executed Process Validation Protocol sent to AIM ImmunoTech
	 
	TOTAL	 	$[***]


 






    	27AIM01.01
	December 22, 2020	Page 17 of 27
	 	CONFIDENTIAL	 



    	 



    

 


Stability
Pull Point Cost and Tables:


 


Stability
for the active Registration Batches will be charged per pull point including testing and storage. If samples stored at 30°C/65%RH
are tested, they will be charged per pull point.


 


Stability
Study Payment Schedule for Registration Batches


 


	Invoice
    Issue Date	Description	Amount
    Due
	Stability

        Initiation
	Stability
                                         Initiation Fee for the Active Registration Batches for Ampligen (Rintatolimod) Sterile
                                         Solution 2.5mg/mL- (non-refundable up to six months)

         

        Microbial:
        2-8°C (1 pull points x 2 pkg. config. x $[***])

        Microbial:
        25°C (1 pull point x 1 pkg. config x $[***])

         
	$[***]
	 

        Month
        14
	12th
                                         month stability pull points for Ampligen (Rintatolimod) Sterile Solution 2.5mg/mL

         

        Microbial:
        2-8°C (1 pull points x 2 pkg. config. x $[***])

        Microbial:
        25°C (1 pull point x 1 pkg. config x $[***])

         
	$[***]
	Month
    20	18th
                                         month stability pull point for Ampligen (Rintatolimod) Sterile Solution 2.5mg/mL

         

        Microbial:
        (1 pull points x 2 pkg. config. x $[***])

         
	$[***]
	Month
    26	24th
                                         month stability pull point for Ampligen (Rintatolimod) Sterile Solution 2.5mg/mL

         

        Microbial:
        (1 pull points x 2 pkg. config. x $[***])

         
	$[***]
	Month
    32	30th
                                         month stability pull point for Ampligen (Rintatolimod) Sterile Solution 2.5mg/mL

         

        Microbial:
        (1 pull points x 2 pkg. config. x $[***])

         
	$[***]
	Month
    38	36th
                                         month stability pull point for Ampligen (Rintatolimod) Sterile Solution 2.5mg/mL

         

        Microbial:
        (1 pull points x 2 pkg. config. x $1,100)

         
	$[***]


 




    	27AIM01.01
	December 22, 2020	Page 18 of 27
	 	CONFIDENTIAL	 



    	 



    

 


	Month
    44	42nd
                                         month stability pull point for Ampligen (Rintatolimod) Sterile Solution 2.5mg/mL

         

        Microbial:
        (1 pull points x 2 pkg. config. x $[***])

         
	$[***]
	Month
    50	48th
                                         month stability pull point for Ampligen (Rintatolimod) Sterile Solution 2.5mg/mL

         

        Microbial:
        (1 pull points x 2 pkg. config. x $[***])

         
	$[***]
	Month
    56	54th
                                         month stability pull point for Ampligen (Rintatolimod) Sterile Solution 2.5mg/mL

         

        Microbial:
        (1 pull points x 2 pkg. config. x $[***])

         
	$[***]
	Month
    62	60th
                                         month stability pull point for Ampligen (Rintatolimod) Sterile Solution 2.5mg/mL

         

        Microbial:
        (1 pull points x 2 pkg. config. x $[***])

         
	$[***]
	 	Total
    for each batch	$[***]
	 	Total
    for 3 Registration batches	$[***]


 


	NOTE:	Release
    testing will be considered time 0; however, if the product is not set within thirty (30) days of manufacturing then the initial
    time point will be required. This cost is not included in this table; therefore, Pii will invoice the AIM ImmunoTech Inc.
    separately for the initial time point.


 




    	27AIM01.01
	December 22, 2020	Page 19 of 27
	 	CONFIDENTIAL	 



    	 



    

 


IV.
Legal and Signatures


 


1.
CONFIDENTIALITY


 


The
parties acknowledge that the Confidentiality Agreement between the parties dated August 13th, 2020 (the "Confidentiality
Agreement") shall continue to govern the parties' respective obligations to one another with regard to the confidential information
each has disclosed to the other and shall continue to disclose to the other in connection with this Agreement. The parties' respective
obligations with regard to any such confidential information shall survive the termination of this Agreement in accordance with
the terms of the Confidentiality Agreement.


 


2.
OWNERSHIP OF MATERIALS AND INFORMATION


 


All
data, information, reports and any and all related documentation, which are developed, generated or derived, directly or indirectly,
by Pii (or by any subcontractor or agent of Pii) for Customer during the course of this Agreement (the "Data"), and
all inventions, discoveries, formulae, procedures, any other intellectual property, and any improvements thereto, whether patentable
or not, which result or evolve directly, during the course of this Agreement or as a result of the services performed hereunder
by Pii (or by any subcontractor or agent of Pii) (together with any Data relating thereto, the "Inventions"), shall
be and remain the sole and exclusive property of Customer if related to the Product; provided, however, any Inventions made, developed
or discovered solely by Pii (or by any subcontractor or agent of Pii) that constitute an invention, improvement or other intellectual
property relating generally (i.e., not solely to the Product) to drug delivery technology, formulation, analysis or manufacturing
process of pharmaceutical products (together with any Data relating thereto, "Pii Inventions"), shall be and remain
the property of Pii, and Pii hereby grants to Customer a perpetual, irrevocable, worldwide, royalty-free, exclusive license (with
the right to sublicense) to develop, use, manufacture and sell such Pii Inventions in connection with the development, use, manufacture
and sale of the Product, provided, further that the foregoing license shall not be exclusive with respect to a Product that is
a non-patented (or non-patent pending) compound. Except as specifically set forth herein, neither Pii nor its employees or agents
shall have or acquire any right, title or interest in Inventions. If related to the Product, Pii shall promptly disclose in writing
to Customer any Inventions. If related to the Product and to the extent not Pii Inventions, Pii shall assign any and all rights
in any Inventions to Customer and shall assist Customer, at no cost to Pii, in perfecting its rights in such Inventions.


 


3.
TERMINATION


 


Customer,
but not Pii, may terminate this Agreement at any time and for any reason at the sole discretion of Customer upon thirty (30) days
advance written notice to Pii. Upon such termination, Customer shall pay all costs incurred by Pii for work performed prior to
the effective date of termination, provided Pii provides written evidence that such costs have been incurred and such work performed.
Either party may terminate this Agreement if the other party is in default of any of its material obligations set forth herein,
and such breach is not cured within sixty (60) days, which time period shall be reduced to ten (10) days for any default of any
monetary obligation, after the breaching party's receipt of a written notice from the non-breaching party that describes such
breach in reasonable detail.


 




    	27AIM01.01
	December 22, 2020	Page 20 of 27
	 	CONFIDENTIAL	 



    	 



    

 


4.
NOTIFICATION OF SUB-CONTRACT LABS


 


Insofar
as Pii anticipates using contract laboratories for some of the activities described in this Agreement, Pii shall notify Customer
when use of such contract laboratories becomes necessary. Pii shall be responsible for assuring that any contract lab used complies
with Pii's obligations hereunder.


 


5.
WARRANTIES


 


Pii
warrants and covenants that it will perform all of its obligations under this Agreement in accordance with all applicable United
States laws and regulations. Without limiting the generality of the foregoing, Pii warrants and covenants that its services hereunder
shall be performed in conformity with the requirements for its services set forth in Section A, Project Definition and Scope above
(the "Requirements") and all Product will be manufactured in compliance with current good manufacturing practices set
forth by the United States Food and Drug Administration ("cGMP"). Pii also warrants and covenants that, to Pii's actual
knowledge, the performance of Pii’s services hereunder (including manufacture of Product) will not infringe or misappropriate
any intellectual property right of any third party, except to the extent such services are provided in accordance with any the
Requirements or other written instructions given by Customer. Except as specifically set forth in this Agreement, Pii MAKES
NO EXPRESS OR IMPLIED WARRANTIES OR COVENANTS, STATUTORY OR OTHERWISE, CONCERNING THE DELIVERABLES. WITHOUT LIMITING THE FOREGOING,
Pii MAKES NO IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE REGARDING THE DELIVERABLES. 


 


6.
ACCEPTANCE OF SHIPMENTS; NON-CONFORMANCE


 


(a)
Pii shall have the right not to deliver Product to Customer if Pii determines that such Product is non-conforming or is otherwise
defective ("Non-Deliverable Product"). As long as, with respect to any batch of Non-Deliverable Product, Pii has performed
its Services in accordance with the terms and conditions of this Agreement: (i) Pii shall be entitled to payment for its Services
actually performed hereunder, and (ii) Pii shall not be responsible for the cost of replacement API required for Pii's replacement
of Non-Deliverable Product.


 




    	27AIM01.01
	December 22, 2020	Page 21 of 27
	 	CONFIDENTIAL	 



    	 



    

 


(b)
Unless otherwise instructed by Customer in writing, Pii will not deliver any batch to Customer unless Pii provides to Customer
a Certificate of Analysis on or before the date of delivery that certifies that the Product meets the product specifications for
the Product set forth in this Agreement (a "COA"). Within thirty (30) days following delivery to Customer, Customer
shall have the right to give Pii notice of rejection of any Product that, in whole or part, fails to conform to the COA. Upon
receipt of a notice of rejection from Customer, Pii shall conduct an internal investigation. Customer shall at all times supply
Pii with any evidence it has that relates to whether any Product delivered to Customer by Pii is non-conforming with the COA.
Failure by Customer to give timely notice of rejection shall constitute acceptance by it of the shipment to which the notice of
rejection would have otherwise applied. In the event of any disagreement between Pii and Customer relating to Product non-conformance
with the COA, the parties will use good faith efforts to reach an amicable resolution of such disagreement. In the event that
resolution cannot be reached, a mutually agreed upon, neutral, independent third party laboratory shall be brought in to resolve
the disagreement upon the request of either party. The results of the independent laboratory shall be binding on the parties and
non-appealable, and the cost of such independent laboratory shall be borne by the party hereunder determined by the independent
laboratory to be the non-prevailing party in such disagreement. Subject to the provisions of Section 7(d) below, for any Product
properly rejected pursuant to this Section 6(b), such Product shall be returned by Customer to Pii at Pii's expense and shall
be replaced by Pii at no extra charge to Customer, subject to the Customer's provision to Pii of materials required pursuant to
the terms of this Agreement for Pii's services, including any active pharmaceutical ingredient ("API"); and in the event
Pii cannot replace such returned Product, it shall refund to Customer the amount paid therefor.


 


(c)
Notwithstanding anything to the contrary contained herein, as long as Pii has performed its Services in accordance with the terms
and conditions of this Agreement, Pii shall not be responsible for the stability of any Product.


 


7.
INDEMNIFICATION


 


(a)
Customer shall indemnify, defend and hold harmless Pii, and Pii’s affiliates, and its and their stockholders, directors,
officers, employees and agents from and against any and all claims, losses, liabilities, lawsuits, proceedings, costs and expenses,
including without limitation, reasonable attorney’s fees and the cost of recalls arising out of or in connection with: (i)
injuries and/or death to humans resulting from the use of any materials provided to Pii by or on behalf of Customer (including
all manufactured products or materials resulting from the provision of Pii's services hereunder), including, without limitation,
claims based on negligence, warranty, strict liability or any other theory of product liability or a violation of applicable laws
or regulations, except to the extent that such injuries or violations are the result of Pii’s negligence or willful misconduct
in performing the services hereunder or breach of any covenant or agreement hereunder, (ii) negligence or willful misconduct in
advertising, labeling, or improper handling and storage of Customer-provided materials or Product by any person other than Pii,
(iii) any instructions given by Customer in connection with any materials provided to Pii by or on behalf of Customer or Pii's
services provided hereunder, (iv) any misrepresentation by Customer or breach by Customer of any covenant, representation, warranty
or agreement hereunder or (v) patent infringement relating to any materials provided to Pii by Customer or Pii's services provided
hereunder to the extent that such infringement does not arise as a result of a breach of any representation or warranty of Pii
hereunder.


 




    	27AIM01.01
	December 22, 2020	Page 22 of 27
	 	CONFIDENTIAL	 



    	 



    

 


(b)
Pii shall indemnify and hold harmless Customer and Customer's affiliates, and its and their stockholders, directors, officers,
employees and agents from and against any and all claims, losses, liabilities, lawsuits, proceedings, costs and expenses, including
without limitation, reasonable attorney’s fees and the cost of recalls arising out of or in connection with: (i) any negligence
or willful misconduct of Pii in performing the services hereunder, or (ii) any misrepresentation by Pii or breach by Pii of any
covenant, representation, warranty or agreement hereunder.


 


(c)
In no event shall either party be liable to the other for indirect damages or consequential damages, including without limitation,
lost profits or revenues.


 


(d)
NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED HEREIN, Pii’S TOTAL LIABILITY TO CUSTOMER FOR COSTS OF REPLACEMENT CUSTOMER
MATERIALS INCLUDING API WITH RESPECT TO ANY BATCH OF PRODUCT, FROM ALL CAUSES OF ACTION OF ANY KIND, SHALL BE LIMITED TO AN AMOUNT
EQUAL TO the LESSER OF (i) THE cost of such CUSTOMER MaterialS INCLUDING API for such
batch OR (ii) TEN PERCENT (10%) OF THE AMOUNT PAID OR PAYABLE TO Pii BY CUSTOMER HEREUNDER FOR THE MANUFACTURE OF SUCH BATCH.


 


EACH
PARTY ACKNOWLEDGES THAT THE FOREGOING LIMITATIONS OF LIABILITY REFLECTS THE ALLOCATION OF RISK SET FORTH IN THIS AGREEMENT AND
CUSTOMER ACKNOWLEDGES THAT Pii ADVISED CUSTOMER THAT Pii WOULD NOT HAVE ENTERED INTO THIS AGREEMENT ABSENT SUCH LIMITATIONS OF
LIABILITY.


 


8.
FORCE MAJEURE 


 


Failure
of any party to perform its obligations under this Agreement (except the obligation to make payments) shall not subject such party
to any liability or place it in breach of any term or condition of this Agreement to the other party if such failure is caused
by any cause beyond the reasonable control of such non-performing party, including, without limitation, acts of God, fire, explosion,
flood, drought, war, riot, sabotage, embargo, interruption of or delay in transportation, a national health emergency or compliance
with any order or regulation of any government entity acting with color of right.


 


9.
GOVERNING LAW


 


This
Agreement shall be governed by and construed in accordance with the laws of the State of Delaware (exclusive of its conflicts
of laws provisions).


 


10.
DISPUTES; ARBITRATION


 


(a)
Except as provided in clause (c) below or in Section 6 with respect to disputes regarding non-conforming shipments, all disputes,
controversies or claims arising out of or relating to the operation or interpretation of this Agreement shall be resolved by arbitration
before one arbitrator in accordance with the Commercial Rules of the American Arbitration Association. The arbitrator shall be
jointly selected by the parties. Any award rendered by the arbitrator shall be final and binding upon the parties and judgment
upon any such award may be entered in any court having jurisdiction thereof. Arbitration shall be conducted in Delaware.


 




    	27AIM01.01
	December 22, 2020	Page 23 of 27
	 	CONFIDENTIAL	 



    	 



    

 


(b)
The arbitrator shall award attorneys' fees and other costs of the arbitration, including the fees and expenses of the arbitrator,
to the prevailing party, as determined by the arbitrator.


 


(c)
Notwithstanding anything to the contrary contained in this Section, in the event of any breach or threatened breach of this Agreement
by either party that the other party believes will cause irreparable harm and damage to it, such party shall be entitled to an
injunction, restraining order restraining such breach or threatened breach by the other party and all other remedies which shall
be available to it at law or in equity and the parties irrevocably submit to the jurisdiction of any state or federal court sitting
in the State of Delaware over any such suit, action or proceeding. Customer irrevocably waives, to the fullest extent permitted
by law, any objection that it may now or hereafter have to the laying of the venue of any such suit, action or proceeding brought
in any such court and any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient
forum.


 


11.
NON-SOLICITATION AND HIRING


 


During
the term of this Agreement and for a period of two (2) years thereafter, regardless of the reason for such termination, neither
party will, directly or indirectly, without the prior written consent of the other party, solicit or hire, as an employee or independent
contractor, any person who is, or was at any time, employed by or under contract with the other party, unless at the time of the
solicitation or hiring, at least one (1) year shall have elapsed since the person was last employed by or under contract with
the other party.


 


12.
MISCELLANEOUS


 


(a)
Waiver; Integration; Modification. The waiver of the breach of any term or provision of this Agreement shall not operate
as or be construed to be a waiver of any other or subsequent breach of this Agreement. This Agreement sets forth the entire agreement
between the parties with respect to the subject matter of this Agreement and merges and supersedes all prior discussions, agreements
and understandings of every nature between them. No modification or amendment to this Agreement or any other agreement with respect
to the subject matter of this Agreement shall be effective unless stated in writing and signed by the parties.


 


(b)
Construction. Whenever the context may require, the singular form of names and pronouns shall include the plural and vice-versa.
The section and subsection headings are included solely for the convenience of the parties and shall not be used in the interpretation
of this Agreement. No rule of construction shall apply to this Agreement that construes any language, whether ambiguous, unclear
or otherwise, in favor of or against any party based on the party that drafted such language.


 


(c)
Counterparts; Electronic Delivery and Signature. This Agreement may be executed in two or more counterparts, each of which
shall be deemed an original and all of which together shall constitute one and the same instrument, and by electronic (PDF) or
facsimile delivery thereof. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, THE PARTIES EXPRESSLY ACKNOWLEDGE AND AGREE THAT
THIS AGREEMENT MAY BE EXECUTED BY ANY PARTY HERETO VIA ELECTRONIC SIGNATURE, AS DEFINED IN THE MARYLAND UNIFORM ELECTRONIC TRANSACTIONS
ACT, MARYLAND CODE, COMMERCIAL LAW ARTICLE, TITLE 21 (THE “ELECTRONIC TRANSACTIONS ACT”), AND THAT ANY SUCH ELECTRONIC
SIGNATURE SHALL HAVE THE SAME FORCE AND EFFECT AS IF IT WAS AN ORIGINAL SIGNATURE AND SHALL BE BINDING TO THE FULLEST EXTENT PERMITTED
UNDER THE ELECTRONIC TRANSACTIONS ACT.


 




    	27AIM01.01
	December 22, 2020	Page 24 of 27
	 	CONFIDENTIAL	 



    	 



    

 


(d)
Survival. No termination or expiration of this Agreement shall relieve the parties hereto of any obligation hereunder which
by their terms are intended to or may survive the termination or expiration of this Agreement.


 


(e)
Relationship Between Parties. Pii's relationship to Customer shall be that of an independent contractor. No persons engaged
by Pii shall be considered under the provisions of this Agreement or otherwise as an employee of Customer. Nothing contained in
this Agreement shall create or imply the creation of a partnership between Customer and Pii and neither party shall have any authority
(actual or apparent) to bind the other.


 


(f)
Delivery. Pii shall choose a commercially reasonable method of freight shipment and carrier for the deliverables hereunder,
unless Customer has specified a particular method of shipment and carrier to Pii. All costs associated with freight, insurance,
packaging and custom duties shall be paid by Customer. Risk of loss, damage and delay shall pass to Customer Ex Works (Incoterms
2010) Pii's shipping dock.


 




    	27AIM01.01
	December 22, 2020	Page 25 of 27
	 	CONFIDENTIAL	 



    	 



    

 


In
order to process this contract, please provide the following information:


 


 


AIM
ImmunoTech Inc. Financial Set Up Form


 


 


Is
a PO required on invoices? _____________Yes_________________________


If
yes, please provide PO along with signed contract


 


Billing
Contact: _Dean Maude________________________________________________


 


Email
Address: _dean.maude@aimimmuno.com______________________________________________


 


Phone
Number: 352-448-7797, ext 105_______________________________________________


 


Billing
Address:


 


Street:
__2117 SW Highway 484


Corporate
Phone: (352) 448-7797


Corporate
Fax: (352)480-4620


____________________________________________________


 


City
and State: __ Ocala, FL 


______________________________________________


 


Zip
Code: __34473


__________________________________________________


 


Country:
__USA___________________________________________________


 


Email
Address to send invoices: ___ dean.maude@aimimmuno.com _______________________________


 


Any
additional email addresses for invoices (if applicable):


 


_vishwajeet.atodaria@aimimmuno.com___________________________________________________________


 


**Please
provide a completed W-9 to accountsreceivable@pharm-int.com


 




    	27AIM01.01
	December 22, 2020	Page 26 of 27
	 	CONFIDENTIAL	 



    	 



    

 


AGREED
AND ACCEPTED


 


	Pharmaceutics
    International, Inc.	 	AIM
    ImmunoTech Inc.
	 	 	 
	/s/John
    Guthrie	 	/s/
    Peter W. Rodino, III, JD
	John
    Guthrie	 	Authorized
    Agent or Representative
	Chief
    Financial Officer	 	Title:
    Chief Operating Officer
	 	 	 
	12/22/2020
    / 1:09 PM EST	 	12/22/2020/
    3:18 PM EST
	Date	 	Date


 


Please
send the fully executed Agreement as a PDF via email to:


 


Michelle
Ava: [***]


Kevin:
[***]


 


Please
email a copy of the Purchase Order (PO) to: accountsreceivable@pharm-int.com


 


Please
remit Project Initiation payment along with signed Agreement to Pii:


 


Pharmaceutics
International, Inc.


P.O.
Box 6259


Hermitage
PA 16148-0923


 


or
transfer funds to:


[***]


 




    	27AIM01.01
	December 22, 2020	Page 27 of 27
	 	CONFIDENTIAL